BioPharma Dive June 10, 2024
Results showed the experimental vaccine produced stronger immune responses in adults than did already licensed products used for comparison in the trial.
Dive Brief:
- Moderna on Monday said a combination flu and COVID-19 shot it’s developing met the goal of a late-stage study, eliciting higher immune responses to the two viruses than did available vaccines when tested among adults 50 years or older.
- Dubbed mRNA-1083, the shot is made up of Moderna’s second-generation COVID vaccine and a candidate for influenza, which have each been tested on their own in separate trials. The company pit mRNA-1803 against Spikevax, its approved COVID vaccine, and against flu shots from drugmakers Sanofi and GSK.
- Moderna said the data showed a single dose of...
Today's Sponsors
Today's Sponsor